Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
60 Degrees Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 0.85 · gapped above the open, then crossed back over prior close. High/low 0.92 at 4:00 am ET, 0.85 at 11:30 am ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“For the year ended December 31, 2025 , our U.S. pharmaceutical distributor accounted for 92 % of our total net product sales and Kodatef sales to our Australian distributor accounted for 6 % of total net product sales ( 95 % and 5 % for the year ended December 31, 2024 , respectively).”
$1M relationship
basisSXTP fy2025 · closed 2025-12 $1M
FILING10-K0001554855-26-000467cik 0001946563
“we entered into the Exclusive License Agreement (the "2014 NUS-SHS Agreement") with National University of Singapore ("NUS") and Singapore Health Services Pte Ltd ("SHS") in which we were granted a license from NUS and SHS with respect to their share of patent rights regarding "Dosing Regimen for Use of Celgosivir as an Antiviral Therapeutic for Dengue Virus Infection" to develop, market and sell licensed products.”
FILING10-K0001554855-26-000467cik 0001946563
“we entered into the Exclusive License Agreement (the "2014 NUS-SHS Agreement") with National University of Singapore ("NUS") and Singapore Health Services Pte Ltd ("SHS") in which we were granted a license from NUS and SHS with respect to their share of patent rights regarding "Dosing Regimen for Use of Celgosivir as an Antiviral Therapeutic for Dengue Virus Infection" to develop, market and sell licensed products.”
FILING10-K0001554855-26-000467cik 0001946563
“We entered into a cooperative research and development agreement with the United States Army in 2014 to complete development of Arakoda for prevention of malaria.”
FILING10-K0001554855-26-000467cik 0001946563
“After deduction of a 5% administrative fee by FSURF, capped at $15,000 annually, and reimbursement of patent prosecution expenses, we will receive 20% of license income and FSURF will receive 80% of license income.”
FILING10-K0001554855-26-000467cik 0001946563
“the Company must make royalty payments equal to 4 % of Net Sales (as defined in the Tufts MC Agreement) of tafenoquine products sold in a format labeled for use in the treatment of babesiosis or 2 % of Net Sales of tafenoquine products sold in a format not labeled for use in the treatment of babesiosis.”
FILING10-K0001554855-26-000467cik 0001946563
“In exchange for the license granted to Yale to us, we agreed to pay Yale a royalty of 2% on net sales of licensed products covering the licensed patents if the licensed produce it branded for treatment of babesiosis and a royalty of 1% on net sales if licensed products covering the licensed product is not specifically branded for treatment of babesiosis.”
FILING10-K0001554855-26-000467cik 0001946563
Watchlist prices, news filtered to it, and its next report on your desk.
60 Degrees Pharmaceuticals, Inc. has 6 disclosed suppliers and 1 disclosed customer. Each one is named in an SEC filing, either 60 Degrees Pharmaceuticals, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
SXTP (60 Degrees Pharmaceuticals, Inc.) has 6 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.